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a b s t r a c t
Human inﬂuenza viruses have their ultimate origin in avian reservoirs and may adapt, either directly or
after passage through another mammalian species, to circulate independently in the human population.
Three sets of barriers must be crossed by a zoonotic inﬂuenza virus before it can become a human virus:
animal-to-human transmission barriers; virus–cell interaction barriers; and human-to-human trans-
mission barriers. Adaptive changes allowing zoonotic inﬂuenza viruses to cross these barriers have been
studiedextensively, generatingkeyknowledge for improvedpandemicpreparedness.Mostof theseadap-
tive changes link acquired genetic alterations of the virus to speciﬁc adaptation mechanisms that can
be screened for, both genetically and phenotypically, as part of zoonotic inﬂuenza virus surveillancevian
wine
ross-species transmission
oonosis
daptation
daptive changes
programs. Human-to-human transmission barriers are only sporadically crossed by zoonotic inﬂuenza
viruses, eventually triggering a worldwide inﬂuenza outbreak or pandemic. This is the most devastating
consequence of inﬂuenza virus cross-species transmission. Progress has been made in identifying some
of the determinants of inﬂuenza virus transmissibility. However, interdisciplinary research is needed to
further characterize these ultimate barriers to the development of inﬂuenza pandemics, at both the level
of the individual host and that of the population.© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
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Fig. 1. Schematics of the barriers to be crossed by zoonotic inﬂuenza viruses to adapt
to and circulate in the human population. (A) Animal-to-human transmission bar-
riers; (B) Virus–cell interaction barriers; 1: Virus attachment; 2: Virus–cell fusion;
3: Viral replication; 4: Virus release; (C) Human-to-human transmission barriers.
C1,  most zoonotic inﬂuenza viruses fail to fully adapt to and circulate in the human
population,  potentially due to their tropism for deeper regions of the respiratory
tract  associated with 2,3 receptor binding afﬁnity, hindering transmissibility and
increasing pathogenicity. C2, rare zoonotic inﬂuenza viruses adapt to and circulate
Waterbird ecology probably contributes to high prevalence
of LPAIV infections among birds of the orders Anseriformes and
Charadriiformes [2]. Feeding and social behaviour as well as popu-
lation sizes and densities of most waterbird species favour mutual420 L.A. Reperant et al. / Va
. Introduction
Inﬂuenza A viruses bear high morbidity and mortality burdens
n humans following yearly seasonal epidemics and occasional
et potentially devastating pandemics. Inﬂuenza pandemics are
aused by inﬂuenza A viruses originating from animal reser-
oirs while inﬂuenza A epidemics are caused by their progeny
ariants—seasonal inﬂuenza A viruses—that have adapted to the
uman species.
Animal inﬂuenza A viruses are abundant. Avian inﬂuenza
iruses circulate in numerous species of wild birds, in particular
aterbirds of the orders Anseriformes (mainly geese, ducks and
wans) and Charadriiformes (mainly gulls and waders), their natu-
al host reservoirs [1,2]. Inﬂuenza A viruses are deﬁned by the sub-
ypes of the hemagglutinin (HA) and neuraminidase (NA) surface
lycoproteins. Virtually all combinations of HA and NA subtypes
ave been found in wild waterbirds, demonstrating the circula-
ion of a large diversity of viruses in these birds. Avian inﬂuenza
iruses generally cause very mild or sub-clinical intestinal tract
nfection in wild birds, potentially resulting in low and transient
mmunity [3,4], which may  allow in these species co-circulation of
nd co-infection with multiple strains and subtypes [5].
Avian  inﬂuenza viruses are the ancestors of all inﬂuenza A
iruses found in other species [1]. They may  be transmitted from
ild waterbirds to poultry, in which they cause mild or sub-clinical
nfection [6]. For this reason, they are referred to as low pathogenic
vian inﬂuenza viruses (LPAIV). LPAIV of the H5 and H7 subtypes
ay evolve towards highly pathogenic avian inﬂuenza viruses
HPAIV) upon transmission into poultry like chickens and turkeys.
PAIV infection usually results in lethal systemic disease in these
pecies. In mammals, occasional transmission of LPAIV from wild
r domestic birds results in either sporadic cases of infection, self-
imiting epidemics, or sustained epidemics that may  eventually
evelop into recurring epidemics caused by adapted variants. The
atter has occurred in humans, swine, horses, and domestic dogs [7].
n these species, speciﬁc lineages of a limited number of subtypes
ave become established. Swine harbour the greatest diversity of
ammalian inﬂuenza A viruses, and may  transmit swine-adapted
nﬂuenza viruses to humans. In mammals, including humans, LPAIV
nd adapted variants typically cause respiratory disease of varying
everity.
HPAIV are rarely transmitted from poultry to other species.
here are notable exceptions. In 2003, a HPAIV H7N7 caused con-
unctivitis in more than 80 people, inﬂuenza-like illness in a few
atients, and fatal respiratory disease in one patient [8]. In 2004,
vian inﬂuenza viruses H7N3 of low and high pathogenic pheno-
ypes caused conjunctivitis and inﬂuenza-like illness in 57 people
9,10]. Lastly, HPAIV H5N1 that emerged in South-East Asia in 1997
11] and currently continue to circulate in poultry, have caused
ore than 570 cases of severe respiratory infection in humans, and
ystemic disease in a wide range of birds and mammals [12,13].
owever, to date, these viruses have probably not become estab-
ished in species other than poultry.
The successful cross-species transmission of avian inﬂuenza
iruses from their natural wild bird reservoirs to humans and the
stablishment of adapted variants in the human population require
he crossing of several barriers [14]. Understanding the changes
hat an animal inﬂuenza virus must undergo to cross these barri-
rs and adapt to the human host to eventually become a pandemic
nﬂuenza virus is essential for better pandemic preparedness. These
arriers can be divided along three major steps deﬁning cross-
pecies transmission: (1) animal-to-human transmission barriers;
2) virus–cell interaction barriers; and (3) human-to-human trans-
ission barriers (Fig. 1). The nature of these barriers as well ashe strategies and ability of inﬂuenza viruses to cross them are the
ubject of this review.in the human population, potentially due to changes in tissue tropism for cells of
the upper respiratory tract associated with 2,6 receptor binding afﬁnity. See text
for more details.
2. Animal-to-human transmission barriers
The ﬁrst barriers to be crossed by zoonotic inﬂuenza A viruses
for successful cross-species transmission from animals to humans
lie at the interface between wild waterbird reservoirs and humans.
This interface may  include bridge or stepping stone species that
the viruses can infect before subsequent transmission to humans.
Prevalence of inﬂuenza virus infection in wild birds or bridge
species, contact between wild birds or bridge species and humans,
and shared use of habitats, limited by geographical, environmen-
tal and behavioural barriers, determine the possible exposure of
humans to zoonotic inﬂuenza viruses. While human exposure to
inﬂuenza viruses of wild birds is relatively rare, human exposure
to inﬂuenza viruses of bridge species, mainly poultry and swine, is
more frequent.
2.1.  Wild-bird-to-human transmission barrierscontacts between individual birds and bird species and there-
fore likely determine virus transmission [15,16]. Furthermore,
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aecal-oral transmission of avian inﬂuenza viruses among water-
irds is most likely facilitated in aquatic habitats. LPAIV are
xcreted in large quantities from the cloaca of infected waterbirds
17] and have been shown to persist for several months under
avourable conditions in environmental reservoirs, such as surface
ater of lakes [18]. Taken together, these factors likely favour
aterbirds over terrestrial birds as main hosts of LPAIV. Contact
ith waterbirds, or shared use of aquatic habitats, thus deﬁne
he behavioural, geographical and environmental attributes of
ild-bird-to-human transmission barriers.
LPAIV prevalence in wild waterbirds generally peaks in early
utumn, when waterbird populations are composed of a high pro-
ortion of juvenile birds that congregate before migration [2,15,16].
t this time of the year juvenile birds have lost their maternal
ntibodies and are immunologically naïve to LPAIV. This proba-
ly contributes to higher prevalence in juveniles than in adults and
o the seasonal dynamics of LPAIV in wild birds. LPAIV prevalence
uring other seasons is typically low to undetectable, although
xceptions occur. For example, high LPAIV prevalence is reported in
pring at Delaware Bay (USA) where large ﬂocks of waders congre-
ate during migration, spurring transmission of LPAIV among these
pecies [2]. As a result, wild-bird-to-human transmission barriers
ay be lowered temporally during migration periods, particularly
n autumn, when LPAIV prevalence is at its highest in waterbirds.
Human  activities leading to cross-species transmission of avian
nﬂuenza viruses directly from wild waterbirds are scarce, and this
s probably a reason for the relatively low occurrence of human
nfections with avian inﬂuenza viruses from wild birds. Waterfowl
unting, wild bird banding, and exceptionally bathing or swimming
n contaminated waters are among the human activities most likely
o permit such cross-species transmission. The waterfowl hunt-
ng season generally opens in autumn, when LPAIV prevalence is
igh in waterbirds, further lowering wild-bird-to-human transmis-
ion barriers. Although rare, serological evidence has indicated past
nfection of duck hunters with LPAIV [19]. Incidentally, individuals
nvolved in wild bird banding activities resulting in contacts with
aterbirds also had rare serological evidence of past LPAIV infec-
ion [20]. The only conﬁrmed acute infection with avian inﬂuenza
irus transmitted directly from wild birds to humans concerns two
lusters of human infection with HPAIV H5N1 and six human deaths
n Azerbaijan, where de-feathering of infected wild swans (Cygnus
pp.) was considered to be the most probable source of exposure
Table 1) [21]. However, wild birds are not reservoirs of HPAIV
5N1, and may  rather be acting as bridge species between poultry
nd humans. In addition, bathing or swimming in contaminated
aters has been incriminated as other possible routes of expo-
ure and infection with HPAIV H5N1 in South-East Asia [22]. Direct
ntranasal or possibly conjunctival inoculation while swimming in
ontaminated waters, inhalation or ingestion of water represents
otential routes of transmission of these particular viruses.
.2.  Bridge-species-to-human transmission barriers
Human demographic growth and consumption patterns may
ave resulted in more opportunities for cross-species transmis-
ion of avian inﬂuenza viruses from wild bird reservoirs to humans
14,23]. In particular, the massive increase in production and con-
umption of poultry, pigs and other livestock and the increasing
ontacts between wild birds and livestock worldwide may  provide
tepping stones to avian inﬂuenza viruses for subsequent transmis-
ion to humans [24].
In  poultry, avian inﬂuenza is typically epidemic, at least in part
riggered by repeated introductions of LPAIV from wild bird reser-
oirs [25]. Transmission of LPAIV from wild birds to poultry may
ccur via shared use of aquatic habitats, shared sources of drink-
ng water or introduction by humans via contaminated utensils or30 (2012) 4419– 4434 4421
vehicles. However, over the past decade, there has been increas-
ing evidence for the establishment of avian inﬂuenza viruses in
poultry. Rare epidemiological surveillance studies revealed infec-
tion of domestic ducks with a large diversity of LPAIV [26]. It is
likely that, in these species, LPAIV have become established and cir-
culate independently of infections in wild birds. In addition, LPAIV
of the H9N2 subtype have become established in aquatic and ter-
restrial poultry in several Asian countries [25]. Several lineages are
co-circulating in different types of poultry and interspecies trans-
mission has favoured reassortments and the evolution of a large
diversity of LPAIV H9N2 in this region [27]. Other LPAIV potentially
circulating in terrestrial poultry independently of wild waterbird
reservoirs include LPAIV H7N2 in the USA, and LPAIV H6N1 in
southern China [25,28]. Recent changes in the epidemiology of
LPAIV H6N1 in China have resulted in the co-circulation of several
lineages in minor terrestrial poultry [29]. Until the emergence of
HPAIV H5N1, epidemics of HPAIV infection in poultry were typically
controlled by measures put in place to halt transmission and spread
of the viruses. HPAIV H5N1 form an exception to this rule, as these
viruses have continued to circulate since their initial demonstra-
tion in 1997 [11] and are now considered endemic in aquatic and
terrestrial poultry in a number of Asian and African countries. Sim-
ilarly to LPAIV H9N2 and H6N1, their establishment and circulation
in different species of poultry have led to extensive reassortments
and the evolution of a large diversity of co-circulating lineages [30].
Circulation and establishment of diverse lineages of LPAIV H9N2,
H6N1, and HPAIV H5N1 in multiple poultry species in Asia and
frequent reassortments between these viruses [29] may well rep-
resent a novel phenomenon associated with the recent massive
increase in industrial poultry populations in this region. Surveil-
lance and study of the epidemiology and evolution of these viruses
are key areas for future research.
The transmission of LPAIV from wild or domestic birds to swine
has resulted in multiple lineages of inﬂuenza viruses that have
become established in swine populations, and are endemic in var-
ious regions of the world [7]. The diversity of swine inﬂuenza virus
subtypes and lineages appears on the rise for the past decades, and
is associated with high rates of reassortments in this species. It is
possible that this is a novel phenomenon likewise in part due to the
massive increase in swine production worldwide [31]. Occasion-
ally, some strains of LPAIV have caused only one or few epidemics
or have been isolated from pigs only sporadically, likely resulting
from sporadic introductions from bird reservoirs without further
establishment. Shared use of habitat or of drinking water with wild
or domestic birds, consumption of carcasses or slaughter offal of
these birds, or introduction by humans via contaminated uten-
sils or vehicles are most likely the sources of LPAIV infection in
swine.
The transmission of LPAIV from birds to other mammals has
resulted in the establishment of equine and canine inﬂuenza virus
lineages in horse and dog populations, respectively; in occasional
inﬂuenza epidemics in farmed American mink (Mustela vison) and
harbour seals (Phoca vitulina); and in sporadic cases of infection
in whales [7]. Contacts with infected birds through shared use of
habitats, shared feeding habits or consumption of infected birds
likely favoured cross-species transmission of LPAIV in these species.
Canine inﬂuenza viruses of the H3N8 subtype currently circulating
in dog populations are exceptions as they originated from an equine
inﬂuenza virus, presumably after consumption of infected horse
meat by racing greyhounds [32,33]. More recently, LPAIV H3N2
have been transmitted from birds to domestic dogs and may  have
established in this species in South-East Asia [34,35]. Among HPAIV,
only HPAIV H5N1 have been transmitted from poultry to a wide
range of wild and domestic birds and mammals [12]. Consump-
tion of infected bird carcasses presumably resulted in the frequent
transmission of these viruses to carnivores and predatory birds [7].
4422 L.A. Reperant et al. / Vaccine 30 (2012) 4419– 4434
Table  1
Reported cases of zoonotic inﬂuenza virus infection determined by viral isolation.
Host of origin Year, place Pathotype Virus subtype Associated activity Ref.
Wild birds Swans, Cygnus spp. 2005, Azerbaijan HP H5N1 De-feathering [21]
Meat  processing
Poultry Chickens and domestic
ducks
1997–present, Asia and
Africa
HP H5N1 Care giving [13]
Butchering
De-feathering
Meat  processing
Possibly consumption
Unknown
Chickens 2007, UK LP H7N2 Visiting bird market [190]
Chickens 2006, UK LP H7N3 Care giving [190]
Chickens 2004, Canada HP H7N3 Care giving [190]
Managing  outbreak
Chickens 2003, Netherlands HP H7N7 Care giving [190]
Managing  outbreak
Chickens, Turkeys 2002–2003, Italy LP H7N3 Managing outbreak [190]
Turkeys 2002, USA LP H7N2 Managing outbreak [190]
Domestic ducks 1996, UK LP H7N7 Care giving [190]
Unknown 2007, Hong Kong LP H9N2 Unknown [191]
Unknown 2003, USA LP H7N2 Unknown [190]
Unknown 2003, Hong Kong LP H9N2 Unknown [191]
Unknown 1999, Hong Kong LP H9N2 Unknown [191]
Unknown 1998, China LP H9N2 Unknown [191]
Mammals Swine  2009, USA LP H1N1 Care giving [192]
Swine  2008, USA LP H1N1 Care giving [192]
Swine 2008, USA LP H1N1 Visiting live-animal
market
[192]
Swine 2007, USA LP H1N1 Care giving [192]
Swine  2007, USA LP H1N2 Visiting county fair [192]
Swine  2007, USA LP H1N1 Visiting county fair [192]
Swine 2006, USA LP H1N1 Contact with patient
with  swine inﬂuenza
infection
[192]
Swine  2006, USA LP H1N1 Unknown [192]
Swine 2005, USA LP H1N1 Butchering [192]
Swine  2005, Canada LP H3N2 Care giving [193]
Swine  2005, USA LP H1N1 Care giving [193]
Swine 2002, Switzerland LP H3N2 Care giving [193]
Swine  1999, Hong Kong LP H1N1 Unknown [193]
Swine 1998, USA LP H1N1 Unknown [193]
Swine  1995, USA LP H1N1 Care giving [193]
Swine  1994, USA LP H1N1 Care giving [193]
Swine  1993, Netherlands LP H1N1 Care giving [193]
Swine  1993, Netherlands LP H3N2 Unknown [193]
Swine 1992, Netherlands LP H3N2 Unknown [193]
Swine  1991, USA LP H1N1 Care giving [193]
Swine 1988, USA LP H1N1 Visiting county fair [193]
Swine  1986, Netherlands LP H1N1 Care giving [193]
Swine  1986, Switzerland LP H1N1 Care giving [193]
Swine  1983, Russia LP H1N1 Care giving [193]
Swine  1982, USA LP H1N1 Unknown [193]
Swine  1980, USA LP H1N1 Visiting market [193]
Swine  1979, USA LP H1N1 Care giving [193]
Swine  1976, USA LP H1N1 Care giving [193]
Swine  1976, USA LP H1N1 Care giving [193]
Swine  1974, USA LP H1N1 Care giving [193]
Harbour seal 1980, USA LP H7N7 Performing necropsy [42]
H
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tP: highly pathogenic; LP: low pathogenic
Animal bridge species infected with inﬂuenza viruses may
ecome sources of infection for humans. The major sources of
uman infection with zoonotic inﬂuenza viruses are poultry and
wine (Table 1). So far, no transmission of equine or canine
nﬂuenza viruses to humans has been reported. However, trans-
ission of avian and human inﬂuenza viruses to domestic dogs
nd cats are increasingly reported [34,36–41]. Domestic carnivores
hus may  represent novel bridge species for cross-species transmis-
ion of zoonotic inﬂuenza viruses, and call for further surveillance
nd research.
Most human cases of infection with zoonotic inﬂuenza viruses
re sporadic and result from close contact with poultry, swine or
heir products, via activities that include occasional contacts atmarkets or fairs, care giving, slaughtering, butchering and prepara-
tion of meat for consumption (Table 1). Similarly, transmission of
LPAIV H7N7 to humans has occurred during necropsy of infected
harbour seals [42]. Such at-risk activities may  lead to inhalation
of infectious fomites, droplets or aerosols, or self-inoculation of
the upper respiratory tract or conjunctiva [22]. Occupational expo-
sure to poultry or swine greatly increases the risk of zoonotic
inﬂuenza virus infection [43]. In the case of HPAIV H5N1, this is
further demonstrated in Egypt, where slaughtering, de-feathering,
and preparation of poultry for consumption are carried out mainly
by women, who  were shown to present a higher risk of infection
than men  [44]. Nonetheless, given the intensive contact between
humans and their livestock worldwide, and the relatively few
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eported cases of zoonotic inﬂuenza virus infections, other barri-
rs likely limit cross-species transmission of inﬂuenza viruses from
nimals to humans.
.3.  Route-of-transmission barriers
The route of transmission of inﬂuenza viruses from animal
eservoirs to humans may  represent another important animal-
o-human transmission barrier. Faecal-oral transmission of LPAIV
ppears favoured by aquatic habitats and associated waterbird
ehaviour, and is the main route of transmission of LPAIV in wild
ird reservoirs [2,15,16]. On the other hand, respiratory transmis-
ion of inﬂuenza viruses appears to be favoured among terrestrial
irds and mammals [7,25]. The ability of zoonotic inﬂuenza viruses
o use the respiratory route of transmission, in particular via
roplet or aerosol transmission, should probably be considered
n important determinant for crossing animal-to-human transmis-
ion barriers.
In  the case of HPAIV H5N1, transmission via the digestive tract
as been suggested in mammals, given the frequent transmission
f these viruses to carnivores [7] and following reports of human
atients presumably infected after consumption of raw duck blood
45]. This is unusual as this route of transmission is generally not
xploited by inﬂuenza viruses in mammals. Experimental stud-
es demonstrated that consumption of infected carcasses led to
PAIV H5N1 infection in cats, ferrets and red foxes (Vulpes vulpes)
46–49]. Further studies demonstrated infection following entry via
he intestinal tract in ferrets, mice, hamsters and cats [49–52]. The
otential use of both respiratory and oral routes of transmission of
PAIV H5N1 in mammals may  contribute to their unusual ability
o cross the species barrier from birds to mammals and increase
he risk of eventual adaptation of these viruses to humans.
.  Virus–cell interaction barriers
Following entry into a new individual host, the main steps in
he inﬂuenza virus replication cycle and interactions of the virus
ith host immune responses represent major virus–cell interaction
arriers that determine the eventual outcome of exposure.
.1.  Virus attachment at site of virus entry
The ﬁrst step in the replication cycle of inﬂuenza A virus is virus
ttachment to host cellular receptors [53]. This is mediated by the
A protein, which binds to glycans expressed on the surface of host
ells. Avian inﬂuenza viruses preferentially bind to glycans har-
ouring sialic acids with 2,3 linkage to galactose [54,55]. These
lycans are abundantly expressed on the surface of avian intestinal
nd respiratory epithelial cells, contributing to the tissue tropism
nd route of transmission of these viruses in wild and domestic
irds [56,57]. It is interesting to note however that they also are
xpressed in other tissues in birds, such as the heart, kidney, brain
nd endothelium [56–58]. The presence and accessibility of glycans
ecognized by avian inﬂuenza viruses at the site of virus entry in
umans are essential for successful cross-species transmission.
The  presence of glycans harbouring sialic acids with 2,3 link-
ge to galactose has been demonstrated on the surface of cells from
iverse tissues of mammals, including humans. Sialic acids with
2,3 linkage to galactose were shown to be expressed in the respi-
atory tract of humans on rare epithelial cells of the nasal mucosa
nd pharynx, focally on tracheal, bronchial and bronchiolar epithe-
ial cells, and more abundantly on alveolar epithelial cells (type II
neumocytes), as determined by use of lectin histochemistry [59].
n other mammals, the same method revealed the presence of these
lycans on the surface of respiratory epithelial cells in the trachea
f swine [60] and horses [61], in the bronchi of domestic dogs [62],30 (2012) 4419– 4434 4423
and  in the lungs of a seal and a whale (species unspeciﬁed) [63].
Binding studies of avian inﬂuenza viruses on tissues of the respira-
tory tract of mammals further demonstrated the presence of target
cells for virus attachment in the lower respiratory tract (mainly
bronchiolar cuboidal epithelial cells, type II pneumocytes and alve-
olar macrophages) of humans, swine, ferrets, and domestic cats
[64–66]. In the trachea and bronchi of humans and ferrets, avian
inﬂuenza viruses were also shown to bind acinar cells of the sub-
mucosal glands and mucus [64], in accordance with the detection
of sialic acids with 2,3 linkage to galactose on these cell types [67]
and in secreted mucins [68]. In extra-respiratory organs, sialic acids
with 2,3 linkage to galactose were detected in humans on Kuppfer
cells in the liver, on neurons in the brain and in the wall of the intes-
tine, and on endothelial cells of the heart and kidney [59]. In the eye,
sialic acids with 2,3 linkage to galactose were present on ocular
and lachrymal duct epithelial cells, in accordance with binding of
avian inﬂuenza viruses to corneal and conjunctival epithelial cells
[69,70].
Different methodologies have been used to detect avian
inﬂuenza virus receptors in mammalian tissues, and although
largely consistent with the observed pathogenesis of avian
inﬂuenza in humans, there are a number of discrepancies between
the results obtained with different methods. Rare binding of avian
inﬂuenza viruses was detected in the trachea of pigs [64], which
contrasts with the reported presence of sialic acids with 2,3
linkage to galactose as determined by lectin histochemistry [60].
Conversely, avian inﬂuenza viruses were shown to abundantly bind
to alveolar macrophages [64], whereas expression of sialic acids
with 2,3 linkage to galactose was  not detected [59]. Furthermore,
evidence of HPAIV H5N1 infection of respiratory epithelial cells in
the upper respiratory tract and trachea of humans, as determined
by immunohistochemistry on cultures of human tissues infected ex
vivo [71] and on tissues from fatal human cases [72] contrasts with
no or rare binding of lectin and avian inﬂuenza virus in these tissues.
There may  be several reasons for this lack of consensus on the tar-
get cells for avian inﬂuenza viruses in the human respiratory tract.
First, the attachment patterns of lectins used in lectin histochem-
istry studies are variable, and depend on the lectin isoform and
pre-treatment regimens applied to the cells or tissues [73]. Second,
the speciﬁcity of inﬂuenza virus for the glycan receptor on the host
cell is determined not only by the type of glycan-sialic acid linkage,
but also by glycan modiﬁcations such as fucosylation, sulphation,
and additional sialylation [74,75] and thus cannot be determined
by techniques that only measure glycan-sialic acid linkages. Third,
the respiratory cells or tissues tested in these studies differed in
their history and origin, which may  have a non-negligible effect on
receptor expression on the cell surfaces. Therefore, further research
is required to determine the afﬁnity of avian and other inﬂuenza
viruses for different parts of the human respiratory tract and other
organs, calling for standardization of the methodology used to
determine the distribution of target cells.
The accessibility of receptors for virus attachment at the portal
of entry in humans is essential for successful cross-species trans-
mission of inﬂuenza viruses from animal reservoirs to humans.
Target cells for avian inﬂuenza viruses are most abundant in deeper
regions of the respiratory tract [64]. Inhaled droplets of small size
deposit abundantly in these regions [76] and may  harbour and
deposit inﬂuenza virus particles in the vicinity of target cells for
attachment. However, mucins secreted by mucous cells along the
respiratory tract can bind to and trap avian inﬂuenza virus parti-
cles, and the ciliated respiratory epithelium continuously propels
particles away from the lower respiratory tract. Although the small-
est droplets reach and may  deposit inﬂuenza virus particles in
the alveoli, the muco-ciliary escalator may prevent avian inﬂuenza
virus deposited along the airways from reaching and infecting their
target cells [77]. In the case of avian inﬂuenza viruses of the H7
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ubtype, which tend to present preferential tropism for ocular tis-
ues in humans [22], mechanical and innate defences associated
ith the human eye likely require invasive insults, such as physi-
al abrasion, to allow avian inﬂuenza virus infection of the ocular
pithelia. Therefore, the relative limited accessibility of receptors
sed by avian inﬂuenza viruses in human hosts may  contribute to
he relative rarity of their transmission to humans.
Sialic acids with 2,6 linkage to galactose are more abundantly
istributed in the upper regions of the respiratory tract [60,68,73]
nd are the cellular receptors used by human inﬂuenza viruses,
dapted to and circulating in the human population [54]. They are
xpressed abundantly on respiratory epithelial cells of the upper
espiratory tract, trachea and bronchi [64,78,79] and likely are more
ccessible to inﬂuenza virus particles than sialic acids with 2,3
inkage to galactose. Preferred afﬁnity for these cellular receptors
hus may  favour successful cross-species transmission of zoonotic
nﬂuenza viruses from animal reservoirs to humans. Sialic acids
ith 2,6 linkage to galactose are not expressed on respiratory or
ntestinal epithelial cells of ducks [80], but are expressed on res-
iratory and intestinal epithelial cells of terrestrial birds, such as
hicken and quail [80]. Accordingly, avian inﬂuenza viruses using
hese cellular receptors do circulate in these species. It is the case for
ome strains of LPAIV H9N2 and of LPAIV and HPAIV of the H7 sub-
ype, which have caused human infection [81–84]. Recently, LPAIV
f the H6 subtype were shown to infect mammalian hosts with-
ut prior adaptation and may  have dual afﬁnity for sialic acids with
2,3 and with 2,6 linkage to galactose [85]. Likewise, respiratory
pithelial cells of swine were shown to harbour both types of sialic
cids [60] and swine inﬂuenza viruses circulating endemically in
ig populations typically bind to sialic acids with 2,3 and with
2,6 linkage to galactose [86,87]. This may  explain the more fre-
uent occurrence of cross-species transmission of swine inﬂuenza
iruses to humans compared to that of avian inﬂuenza viruses.
The  receptor binding site of inﬂuenza virus HA protein is a shal-
ow depression at the top of the protein to which sialic acids bind.
ey amino-acids within or close to the receptor binding site and
onferring 2,3 or 2,6 receptor binding afﬁnity have been identi-
ed in the HA protein of inﬂuenza viruses of the H1, H2, H3, H4, H5
nd H9 subtypes (Table 2).
Portals of entry other than the respiratory epithelium were sug-
ested for HPAIV H5N1, yet the sites of initial virus attachment and
nfection following non-respiratory routes of entry remain unclear.
n intestinal portal of entry has been demonstrated experimen-
ally in ferrets, mice, hamsters and domestic cats [49–52]. However,
ntestinal epithelial cells have not been found infected in these
pecies and the initial target cells used by HPAIV H5N1 follow-
ng intestinal inoculation are unknown. Neurons may  represent
andidates for initial infection, as their cellular surface harbours
ialic acid with 2,3 linkage to galactose in humans [59], allow-
ng attachment of avian inﬂuenza viruses. Neurons are abundant in
he olfactory epithelium of the upper respiratory tract, as well as
n the wall of the intestinal tract. Neuronal transmission from the
asal cavity to the olfactory bulb has been demonstrated for HPAIV
5N1 in mice, suggesting a potential neuronal route of entry of the
irus in this species [88]. In ferrets, lesion patterns in the olfac-
ory bulb indicate similar neuronal spread of HPAIV H5N1 from the
asal cavity to the brain [89–91]. However, no evidence of neuronal
ransmission initiated in the intestinal wall has been found in cats
noculated directly in the intestine, and it was suggested that these
iruses may  use microfold (M)  cells for initial infection and entry
52]..2. Virus and cell fusion
Following  virus attachment to cellular receptors, the HA pro-
ein of inﬂuenza viruses mediates the fusion of the virus and host 30 (2012) 4419– 4434
cell  membranes [53]. The HA protein needs to be cleaved into
two polypeptide chains (HA1 and HA2) by host proteases to allow
membrane fusion [92]. Only cleaved HA protein can undergo an
irreversible conformational change triggered by the low pH of the
host cell endosome that has internalized the virus, resulting in
fusion of the virus envelope with the endosomal membrane. The
presence of host proteases catalyzing HA cleavage is necessary at
the site of virus entry to initiate infection following cross-species
transmission of zoonotic inﬂuenza viruses (Table 2).
The  cleavage site of LPAIV HA protein is characterized by a single
arginine residue, and is cleaved by extracellular trypsin-like pro-
teases, which must be present at the portal of entry for infection
with LPAIV to take place. These enzymes are present in a lim-
ited number of host tissues, contributing to the development of
a localized infection [92]. Trypsin-like proteases are abundant in
the intestinal tract of birds [56,57]. In mammals, trypsin-like pro-
teases have been shown to be present in the respiratory tract of
swine, mice, rats and humans and can activate cleavage of inﬂuenza
virus HA protein in vitro [93–102] (Table 3). In humans, those
include the serine protease TMPRSS2, a type II transmembrane
protease [103], and human airway trypsin-like proteases (HAT),
which occur in both transmembrane and soluble forms [99,100].
The role these enzymes play in vivo during infection with inﬂuenza
virus of zoonotic or human host origin is not known. Some bac-
terial proteases also appear capable of activating the HA protein
by proteolytic cleavage in vitro and of increasing viral titers and
pathogenicity of inﬂuenza virus in mice [104–106]. Presence of bac-
teria secreting such proteases in the human respiratory tract may
favour cross-species transmission of avian inﬂuenza viruses.
In  contrast to the cleavage site of LPAIV HA protein, that of
HPAIV HA protein is characterized by several basic amino-acids
and is cleaved by ubiquitous intracellular subtilisin-like proteases,
present in a wide range of avian and mammalian cells [92]. There-
fore, HPAIV are typically released in an infectious form from
infected cells, with cleaved HA proteins [107]. Together, these char-
acteristics allow for a more diverse tissue tropism and infection of
cells in multiple organs of avian and in some cases, mammalian
hosts. In poultry, the high pathogenicity of HPAIV is associated
with their multi-basic cleavage site [6]. However, the presence
of a multi-basic cleavage site does not necessarily confer high
pathogenicity to inﬂuenza viruses in mammals. For example, the
H7 protein of equine inﬂuenza viruses has a tetra-basic cleavage
site, which contributes to high pathogenicity when introduced into
an avian virus genetic background, resulting in fatal disease in poul-
try [108]. Yet, these viruses do not cause severe disease in horses,
and infection is restricted to the respiratory tract. Similarly, HPAIV
H7N3 that emerged in 2004 caused infection restricted to the eye
and respiratory tract in humans, resulting in mild to moderate dis-
ease [10]. Conversely, the multi-basic cleavage site of HPAIV H5N1
that emerged in 1997 was a determinant of high pathogenicity
and wide tissue tropism in mammals. A 1997 HPAIV H5N1 strain
that was pathogenic in mice was highly attenuated upon replace-
ment of the multi-basic cleavage site with that of a low pathogenic
inﬂuenza virus [109]. However, different strains of HPAIV H5N1
exhibit variable levels of pathogenicity in mammals [110] and other
determinants of pathogenicity besides the multi-cleavage site have
been identiﬁed in these viruses [111].
3.3. Virus replication
Following the fusion of the virus envelop and cellular mem-
branes, proton pores in the virus envelop formed by matrix 2
(M2) proteins open. They expose matrix 1 (M1) proteins and the
virus ribonucleoprotein (vRNP, composed of the viral RNA seg-
mented genome coated with nucleoproteins and proteins of the
polymerase complex) to increased concentration of protons [53].
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Table  2
Known mutations and associated mechanisms of adaptation of zoonotic inﬂuenza viruses to human hosts via the crossing of virus–cell interaction barriers.
Virus–cell interaction barrier Protein Mutation Adaptive mechanism Ref.
Virus attachment HA N154S Increases 2,6 binding in H5 subtype [194]
N182K Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194,195]
E190D Increases  2,6 binding in H1 subtype [86,196]
Q192R Increases 2,6 binding and decreases 2,3 binding in H5 subtype [195]
D222G Increases 2,3 binding in H1 subtype [75,197]
Q222L Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
S223N  Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
G224S  Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
G225D Decreases 2,3 binding in H1 and H9 subtypes [81,86,196]
Q226L Increases 2,6 binding and decreases 2,3 binding in H2,  H3, H4,
H5  and H9 subtypes
[81,86,198,199]
S227N  Increases 2,6 binding and decreases 2,3 binding in H5 subtype [200,201]
G228S  Decreases 2,3 binding in H3 subtype [86,198,201]
Increases 2,6 binding in H2 and H5 subtypes
L129V + A134V Increases 2,6 binding possibly in H5 subtype [202]
G139R + N182K Increases 2,6 binding in H5 subtype [194]
Q192R + S223N Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
Q222L + G224S Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
S227N  + NST158 − 150NNA Increases 2,6 binding in H5 subtype [203]
N158S + Q226L + N248D Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194,204]
N182K + Q222L + G224S Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
Q192R + Q222L + G224S Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
Q222L  + S223N + G224S Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
NST158-150NNA + K193R + Q226L + G228S Increases 2,6 binding and decreases 2,3 binding in H5 subtype [205]
N182K  + Q222L + S223N + G224S Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
Q192R  + Q222L + S223N + G224S Increases 2,6 binding and decreases 2,3 binding in H5 subtype [194]
N182K + Q192R + Q222L + S223N + G224S Increases 2,6 binding in H5 subtype [194]
Virus–cell  fusion HA  Single R cleaved site Allows cleavage by extracellular host proteases restricted to
respiratory  tract in humans
[92]
Multi-basic  cleaved site Allows  cleavage by ubiquitous intracellular host proteases present
in various tissues in humans
[92]
Viral  replication PB1 + PB2 Unknown Increases polymerase activity of HPAIV H5N1 in human cells
(unknown  mechanism)
[126]
PB2 E158G  Increases polymerase activity of HPAIV H5N1 in human cells
(unknown  mechanism)
[121]
T271A Increases polymerase activity of LPAIV H3N2 in human cells
(unknown  mechanism)
[124]
Q591 K Increases polymerase of HPAIV H5N1 activity in human cells
(unknown  mechanism)
[120]
E627 K Increases polymerase activity by increasing PB2 and NP binding in
human cells
[118]
D253N + Q291 K Increases polymerase activity of LPAIV H9N2 in human cells
(unknown  mechanism)
[122]
G590S  + Q591R Increases polymerase activity of 2009 pandemic H1N1 virus in
human  cells (unknown mechanism)
[123]
PA  T552S Increases polymerase activity of avian inﬂuenza viruses in
mammalian  cells and increases pathogenicity in mice (unknown
mechanism)
[125]
NP  + PB2 N319K + D701 N Increases polymerase activity by increasing binding of vRNP to
importin-1, and shifting nuclear import dependency from
importin-3  to importin-7 in human and other mammalian cells
[112]
Virus  release NA I275V Increases 2,6 substrate speciﬁcity in N2 subtype [133]
Viral  escape from host
immune  responses
HA  Antigenic shift Escapes pre-existing humoral immunity [134]
NS1 D92E  Confers HPAIV H5N1 resistance to IFN-, IFN- and TNF-
(unknown mechanism)
[139]
P42S Prevents double-stranded RNA-mediated activation of NF-B and
IRF-3 pathways during HPAIV H5N1 infection
[140]
L103F + I106M Allows binding of HPAIV H5N1 NS1 protein and CPSF30 resulting
in  decreased INF-mRNA production
[141]
PDZ  domain ligand in C-terminus Disruption of protein-protein interactions, including impairment
of  IFN-stimulated signaling, disruption of tight junctions, and
reduction  of apoptosis
[142–145]
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he lower pH results in the dissociation of M1  proteins form-
ng the nucleocapsid and release of vRNP into the cell cytoplasm.
RNP are transported into the nucleus, where viral replication is
nitiated. The nucleoprotein (NP) and proteins of the polymerase
omplex (basic polymerase 1 and 2 proteins PB1, PB2 and acidic
olymerase protein PA) have nuclear localization signals, ensur-
ng nuclear transport of vRNP. Upon entry into the nucleus, the
roteins of the polymerase complex catalyze mRNA synthesis andknown mechanism associated with apoptosis pathway
ulation
[150]
viral replication. Compatibility of the proteins of the polymerase
complex with each other and with host cell proteins, governing
nuclear import of vRNP and viral transcription and replication, is a
prerequisite for efﬁcient viral replication [56].Transport across the nuclear envelop has recently been
suggested as a virus–cell interaction barrier for cross-species trans-
mission of inﬂuenza virus [112]. Nuclear transport of inﬂuenza
virus vRNP is mediated by importin- proteins, which recognize
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Table  3
Trypsin-like proteases found in mammalian respiratory tract.
Species Trypsin-like protease Producing cells Regions of the respiratory tract Ref.
Swine Serine protease Mast cells Lung [93,94]
Mouse Tryptase  Clara Clara cells Bronchiolar epithelium [95]
Rat Tryptase  Clara Clara cells Bronchiolar epithelium [95]
Mini-plasmin  protease Epithelial cells Bronchiolar epithelium [96]
Ectopic  anionic trypsin I Stromal cells Bronchiolar epithelium [96]
Human Prostasin  Airway epithelial cells, type II
pneumocytes, submucosal
glandular  cells
Nasal,  tracheal, bronchial,
bronchiolar  and alveolar epithelia
[98]
TMPRSS2 Airway epithelial cells, type II
pneumocytes, submucosal
glandular  cells
Nasal,  tracheal, bronchial,
bronchiolar  and alveolar epithelia
[98]
Human airway
trypsin-like proteases
Ciliated epithelial cells,
submucosal  glandular cells
Tracheal and bronchial epithelium [99–101]
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RNP nuclear localization signals, as part of the classical nuclear
mport pathway. Six isoforms of importin- have been described
n humans. The nuclear transport of vRNP of HPAIV H7N7 (SC35)
nd H7N1 subtypes was shown to be mediated by importin-1
nd importin-3 in mammalian cells. In contrast, the nuclear
ransport of vRNP of a mouse-adapted variant of the H7N7 virus
SC35M), of HPAIV H5N1 isolated from a fatal human case, and
f seasonal inﬂuenza virus H3N2 was mediated by importin-1
nd importin-7 [112]. D701N substitution in the PB2 protein and
319K substitution in the NP protein of the H7N7 virus were asso-
iated with increased binding to importin-1 and switch from
mportin-3 to importin-7 dependency, resulting in increased
uclear transport, transcription and viral replication in mammalian
ells (Table 2) [112–115].
Another  key amino-acid associated with increased polymerase
ctivity and viral replication in mammalian cells is that at position
27 in the PB2 protein (Table 2) [111]. Most avian inﬂuenza viruses
ave a glutamic acid residue at position 627 of the PB2 protein while
uman inﬂuenza viruses typically have a lysine residue at that
osition. E627K substitution has been shown to increase viral repli-
ation and expand tissue tropism in mice, and is acquired rapidly
pon adaptation of inﬂuenza virus in this species. Conversely, the
resence of a glutamic acid at this position severely reduces viral
eplication efﬁciency in mice (for a review see Ref. [111]). PB2 627E
esidue contributes to the temperature sensitivity of avian virus
eplication in mammalian cells [116]. Viral replication of a strain
f HPAIV H5N1 with substitution E627K was improved in vitro
t 33 ◦C, which is the temperature of the upper respiratory tract
f mammals. Accordingly, this substitution led to increased viral
iters of HPAIV H5N1 in the nasal turbinates of infected mice [117].
he mechanism behind improved replication associated with PB2
627K substitution has recently been partly elucidated. PB2 protein
ith a glutamic acid at position 627 was shown to be selectively
nd potently restricted by a dominant inhibitory activity in human
ells, and failed to bind to NP proteins and assemble into vRNP,
esulting in decreased transcription, replication and viral produc-
ion [118]. The necessary compatibility between PB2 protein with
27K residue and the NP protein has further been demonstrated
or HPAIV H5N1 clade 2.2 [119].
A number of HPAIV H5N1 isolated from human cases, and 2009
andemic inﬂuenza viruses H1N1 have not acquired PB2 E627K
ubstitution, despite their ability to efﬁciently infect humans. Other
daptive mutations have been found to increase replication of
oonotic inﬂuenza viruses with PB2 627E residue in mammalian
ells, in association with increased pathogenicity in mice, providing
dditional pathways for adaptation to human or other mammalian
osts [120–125] (Table 2). Mutations in both PB1 and PB2 have
een shown to enhance viral replication of a strain of HPAIV H5N1,yet  the speciﬁc mutations responsible for this effect have not been
identiﬁed [126] and the role of many speciﬁc mutations in enhanc-
ing viral replication in mammalian cells remains largely unknown.
Genomic analyses of avian and human inﬂuenza viruses have iden-
tiﬁed amino acids in all gene segments that characterize the host
origin of the viruses, and may  represent adaptive changes for bet-
ter replication in human cells [127,128]. Many of these amino-acid
signatures are present in the PB2, PA and NP proteins, and are asso-
ciated with functional domains involved in protein interactions
potentially essential for viral replication.
3.4. Virus release
Following inﬂuenza virus transcription, viral proteins are syn-
thesized and progeny virions are assembled and released from
infected cells [53]. Inﬂuenza virus integral membrane proteins
(HA, NA and M2  proteins) are synthesized on membrane-bound
ribosomes, translocated to the endoplasmic reticulum and Golgi
apparatus, and transported to the apical membrane of polarized
cells. vRNP formed in the nucleus associate with M1  and nuclear
export proteins (NEP; formerly non-structural protein 2 NS2), and
are exported into the cytoplasm. NEP proteins have been shown to
harbour nuclear export signals. Interactions between M1 and M2
proteins promote virus assembly and packaging of progeny viruses.
The sialidase activity of the NA surface protein facilitates release
of virions by cleaving attachment of HA proteins and sialic acids
present on the cell membrane. Virus–host interaction barriers likely
occur at the nuclear and cellular membranes upon nuclear export
of vRNP and release of progeny viruses.
Inﬂuenza virus NEP and NP proteins have been shown to interact
with exportin protein 1 (hCRM1) [129,130]. However, it remains
unknown whether species-speciﬁc differences in the use of vari-
ous exportin proteins by these and the other proteins synthesized
by avian and mammalian inﬂuenza viruses exist in a similar way
to what has been described for their use of importin-. Further-
more, mitogen-activated protein (MAP) kinases appear to control
the active nuclear export of vRNP, yet the interactions of viral pro-
teins with these enzymes have not been described [131]. Exportin
proteins and MAP  kinase pathways may  provide ground for adap-
tive changes to optimize nuclear export of inﬂuenza virus vRNP in
mammalian cells.
The  balance between HA and NA activities has long been rec-
ognized as an essential determinant of the adaptation of inﬂuenza
viruses to a novel host. The sialidase activity of the NA protein plays
several roles during the inﬂuenza virus replication cycle [132]. First,
it may  promote viral attachment by degrading mucus present along
the respiratory tract and favouring HA access to underlying recep-
tors, and by removing sialic acids located near the HA receptor
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inding site. Second, it is essential for virus release by prevent-
ng HA-mediated aggregation of budding viruses by desialylation
f viral and cellular glycans. The substrate speciﬁcity of the NA pro-
ein must therefore correlate with HA receptor binding afﬁnity to
alance and optimize HA-mediated attachment and release of virus
articles. A slow increase in NA enzymatic speciﬁcity for sialic acids
ith 2,6 linkage to galactose has been demonstrated in the N2
rotein from the emergence of pandemic inﬂuenza virus H2N2 in
957 to recent seasonal inﬂuenza viruses H3N2 [133] (Table 2).
et, NA 2,3 speciﬁcity is typically conserved in human inﬂuenza
iruses, and may  be required for escape from entrapment in res-
iratory mucins. Such enzymatic speciﬁcity may  be particularly
mportant for avian inﬂuenza viruses, which bind to sialic acids
ith 2,3 linkage to galactose expressed on respiratory mucins.
ther compensatory changes in the NA or HA proteins may  over-
ome a lack of balance between HA receptor binding afﬁnity and NA
ubstrate speciﬁcity, providing additional pathways for adaptation
o novel hosts. In particular, lack or reduced NA sialidase activity can
e compensated by decreased HA afﬁnity for its cellular receptors
56].
.5. Viral escape from host immune responses
Human hosts mount innate and adaptive immune responses
pon infection with inﬂuenza virus [134]. Innate immune
esponses are contemporary to the acute infection. Pro-
nﬂammatory cytokines (such as tumor necrosis factor TNF-
nd type I interferons IFN-/) are produced by infected as well
s dendritic cells and induce uninfected cells to enter into an
nfection-refractory state, preventing virus replication. They also
ttract natural killer and antigen-presenting cells to the site of
nfection. Cellular and humoral adaptive immune responses,
overned by T-helper lymphocytes, immunoglobulin-producing
-lymphocytes and cytotoxic T-lymphocytes, appear later and
ontribute to inﬂuenza virus clearance, and to the development
f immune memory. Inﬂuenza viruses exhibit various strate-
ies to evade or disrupt host immune responses, which likely
lay signiﬁcant roles in cross-species transmission of zoonotic
nﬂuenza viruses. However currently, it is poorly understood how
he requirement for escape from host immune responses can limit
he ability of a virus to cross to a new species.
The innate immune response forms the ﬁrst line of defence
gainst inﬂuenza virus, concurrent to the acute infection, and can
e modulated by inﬂuenza virus non-structural protein 1 (NS1)
Table 2) [135]. The NS1 protein has multiple functions during
nfection. It regulates the synthesis of viral RNA and virus-induced
poptosis. It also binds double-stranded RNA in vivo and represses
ost cellular antiviral responses by multiple mechanisms. These
echanisms include the inhibition of the post-transcriptional pro-
essing of IFN-/-independent cellular antiviral pre-mRNAs, the
nhibition of the activation of the double-stranded RNA-activated
rotein kinase R (PKR), and the blocking of IFN- by preventing the
ctivation of transcription factors [135]. The NS1 protein also inter-
cts with the cellular protein retinoic acid-inducible gene product
 (RIG-I) further impairing IFN induction [136], and preventing the
aturation of human primary dendritic cells, thereby limiting host
-cell activation as part of the adaptive immune response [137].
Microarray analyses have demonstrated that the deletion of
he NS1 gene from inﬂuenza virus genome increased the number
nd magnitude of expression of host cellular genes implicated in
he IFN, NF-B (nuclear factor kappa-light-chain-enhancer of acti-
ated B-cells) and other antiviral pathways [138]. The A/WSN/33
nﬂuenza virus containing the NS1 of the 1918 pandemic inﬂuenza
irus H1N1 was more effective at inhibiting a subset of IFN-
timulated genes in human lung epithelial cells than the parental
irus strain. The NS1 protein of HPAIV H5N1 confers resistance30 (2012) 4419– 4434 4427
against  the antiviral effects of IFN-, IFN- and TNF- in vitro [139]
and can result in reduced production of IFN- and increased viral
replication [140,141] (Table 2). Recently, a PDZ domain ligand at
the C-terminus of the NS1 proteins of HPAIV H5N1 and 1918 pan-
demic inﬂuenza virus H1N1 was  shown to bind a variety of human
PDZ domains, while the corresponding motif at the C-terminus of
the NS1 protein of most human inﬂuenza viruses bound little or not
at all [142]. PDZ domains are protein–protein recognition domains
that are involved in a variety of cell-signaling pathways. The molec-
ular consequences of the interactions between the NS1 protein of
these viruses and human PDZ domains include impairment of IFN-
stimulated signaling, disruption of tight junctions, and reduction
of apoptosis, suggesting that several pathways are available for
inﬂuenza viruses to manipulate host cellular responses to infection
[143–145].
Apoptosis—programmed cell-death—is a potent antiviral
response that is regulated by inﬂuenza virus upon infection to sup-
port its propagation [131]. However, both pro- and anti-apoptotic
mechanisms associated with inﬂuenza virus proteins have been
described, and their consequences on viral replication or host cell
defense is still under debate, calling for further research [131]. The
NA, NS1, M1  and PB1-F2 proteins have been shown to regulate
apoptosis pathways [131,145–149]. Substitution of N66S in the
PB1-F2 reading frame was  shown to increase apoptosis, and was
associated with increased pathogenicity and viral replication of
HPAIV H5N1 and 1918 pandemic inﬂuenza virus H1N1 in mice
(Table 2) [150]. Inhibition of apoptosis impairs inﬂuenza virus
replication, and it has been suggested that this effect is associated
with retention of vRNP in the nucleus, preventing formation of
progeny particles [131]. In addition, pro-apoptotic features of the
PB1-F2 protein may  result in speciﬁc depletion of lymphocytes
during inﬂuenza virus infection, and may limit the release of
pro-inﬂammatory cytokines, thus interfering with both innate and
adaptive immune responses [151].
It is important to note that different mechanisms of disrup-
tion of host immune responses characterize zoonotic, pandemic
and seasonal inﬂuenza viruses. This calls for further research on
their impact on these viruses’ epidemiological and evolutionary
dynamics in the human host.
4. Human-to-human transmission barriers
Following successful inﬂuenza virus infection of human hosts
and production and release of progeny viruses from infected cells,
the last barriers to be overcome by zoonotic inﬂuenza viruses are
the human-to-human transmission barriers. These pave the way  to
the establishment and continued circulation of adapted inﬂuenza
virus variants in the human population, independently of animal
reservoirs. Human-to-human transmission barriers have success-
fully been crossed by zoonotic inﬂuenza viruses only four times
since the beginning of last century, and appear to represent the
major obstacles for cross-species transmission and adaptation of
zoonotic inﬂuenza viruses to the human host. Acquisition of trans-
missibility by zoonotic inﬂuenza viruses, escape from pre-existing
herd immunity and the ability of transmissible variants to be main-
tained in the human population are the major components of the
human-to-human transmission barriers.
4.1. Acquisition of transmissibility
The  initial component of the human-to-human transmission
barriers is the efﬁciency by which zoonotic inﬂuenza viruses
transmit among human hosts. Viral, host and environmental deter-
minants of inﬂuenza virus transmissibility in humans have been
identiﬁed. Inﬂuenza viruses in humans are transmitted by direct
4428 L.A. Reperant et al. / Vaccine 30 (2012) 4419– 4434
Table  4
Amino-acid substitutions associated with changes in inﬂuenza virus transmissibility.
Virus subtype Protein Substitution Associated changes Effect on transmissibility Ref.
H9N2 HA Q226L Confers 2,6 receptor binding
afﬁnity
Increased contact transmission
in  ferrets
[156]
H1N1 (1918) HA D190E + D225G Confers 2,3 receptor binding
afﬁnity
Abrogated contact
transmission in ferrets
[157]
H1N1  (with 1918 HA and NA) PB2 E627K Increases viral replication in
mammalian cells
Allows aerosol transmission in
ferrets
[158]
H5N1 (HP) PB2 K627E Decreases viral replication in
mammalian cells
Impairs contact transmission
in  guinea pigs
[159]
H3N2 (seasonal) PB2 K627E Decreases viral replication in
mammalian cells
Impairs aerosol transmission in
guinea pigs
[159]
H5N1 (HP) PB2 D701N Increases viral replication in
mammalian cells
Improves contact transmission
in  guinea pigs
[159]
H3N2 (seasonal) PB2 D701N Increases viral replication in
mammalian cells
Improves aerosol transmission
in  guinea pigs
[159]
H1N1 (PR8) M Uncharacterized: M
protein  of pandemic
virus  H1N1 (2009)
Unknown Confers aerosol transmission in
guinea pigs
[160]
H1N1 (2009 in a H3N2 swine M Uncharacterized: M Unknown Improves aerosol transmission [160]
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background)
protein  of pandemic
virus  H1N1 (2009)
nd indirect contact, and via production and inhalation of aerosols
r large droplets [152] favoured at low temperatures and high rel-
tive humidity levels [153,154]. Airborne transmission of inﬂuenza
irus among mammalian hosts is thought to be mediated by infec-
ion of the upper regions of the respiratory tract, resulting in
xcretion of high viral titers, and facilitated by 2,6 receptor bind-
ng afﬁnity of the HA protein [65,66,78,155]. The epithelium of the
pper regions of the respiratory tract is composed of mostly ciliated
pithelial cells, which abundantly express sialic acids with 2,6
inkage to galactose [79]. Accordingly, human inﬂuenza viruses
ind abundantly to cells in the upper regions of the respiratory
ract of humans while attachment of HPAIV H5N1 and other avian
nﬂuenza viruses is not or rarely detected [64,78]. Several amino-
cid substitutions in the HA and PB2 proteins affecting receptor
inding afﬁnity and viral replication in mammalian cells have been
hown to permit or abrogate contact or aerosol transmission of
nﬂuenza viruses in animal models [156–160] (Table 4). The asso-
iated mechanisms remain nevertheless elusive.
Although progress has been made in identifying determinants of
nﬂuenza virus transmissibility, 2,6 receptor binding afﬁnity and
nfection of the upper regions of the respiratory tract, resulting in
xcretion of high viral titers, appear not sufﬁcient to allow airborne
ransmission of avian inﬂuenza viruses in mammals. LPAIV H9N2
ith 2,6 receptor binding afﬁnity were transmitted via contact
ut not aerosols in ferrets [156]. Likewise, most HPAIV H5N1 engi-
eered to preferentially attach to sialic acids with 2,6 linkage to
alactose replicate in the upper regions of the respiratory tract still
o not efﬁciently transmit in animal models, at best only by con-
act [155]. A handful substitutions in the HA protein of HPAIV H5N1,
f which only some were necessary to confer 2,6 receptor bind-
ng afﬁnity, were necessary to allow airborne transmission of the
irus in ferrets [161]. It has been suggested that besides 2,6 recep-
or binding afﬁnity and replication to high viral titers in the upper
egions of the respiratory tract, more subtle differences in recep-
or preference and the formation and release of single inﬂuenza
irus particles, mediated by balanced activity of the HA and NA
roteins, represent additional requirements for efﬁcient airborne
ransmission [155].
.2.  Escape from pre-existing herd immunityPre-existing immunity in the human population is known to
ave a marked effect on the epidemic dynamics of inﬂuenza virus.
n particular, the antigenic shift following the introduction ofin  guinea pigs
transmissible  zoonotic inﬂuenza viruses largely contributes to the
development of inﬂuenza pandemics, whereby viral spread in the
population is unhampered by pre-existing immunity. The antigenic
shift allows pandemic viruses to invade greater portions of the
human population as well as greater portions of the respiratory
tract within individual hosts, typically resulting in more extensive
epidemic waves and more severe disease [162,163].
The pandemic of 1918 was triggered by inﬂuenza virus H1N1
and resulted in 30–50 million deaths [164]. The animal origin of this
virus is unclear. Phylogenetic analyses of the eight gene segments
of a reconstructed 1918 H1N1 virus [165] placed all gene sequences
in the mammalian clade, which contains human and swine strains.
However, they were found more closely related to avian isolates
than to any other mammalian isolates of inﬂuenza virus [166–171].
Further analyses suggested that the pandemic virus likely resulted
from reassortment events between mammalian and avian viruses
[172]. In particular, the PB1 and PA genes appeared to be of recent
avian origin. The pandemic viruses of 1957 and 1968 resulted from
reassortment events between avian inﬂuenza viruses and previ-
ously circulating human strains [164]. In 1957, the HA, NA and
PB1 proteins of an H2N2 avian inﬂuenza virus were introduced
in the previously circulating H1N1 human strain. In 1968, the HA
and PB1 proteins of an H3 avian inﬂuenza virus were introduced in
the previously circulating H2N2 strain. The host species, whether
avian or mammalian, that sustained these reassortment events are
unknown. The ﬁrst pandemic of the 21st century was  caused in
2009 by an inﬂuenza virus H1N1 of swine origin, resulting from
reassortment events between swine, avian and human inﬂuenza
virus strains [173]. The HA, NP, NS and polymerase genes emerged
from a triple-reassortant virus circulating in North American swine.
The source triple-reassortant itself comprised genes derived from
avian (PB2 and PA), human H3N2 (PB1) and classical swine (HA,
NP and NS) lineages. The NA and M genes of the pandemic virus
originated from the Eurasian avian-like swine H1N1 lineage.
Reassortment may  represent the most efﬁcient adaptive avenue
leading to the generation of pandemic inﬂuenza viruses, allowing
antigenic shift by acquisition of novel surface glycoproteins on the
one hand, and better ﬁtness associated with the maintenance of
viral segments adapted to mammalian hosts on the other. Remark-
ably, in all pandemic viruses except the recent H1N1 strain, the
PB1 gene was of avian origin, and in all pandemic viruses, the HA
gene was of animal and non-human origin. Introductions of HA
and PB1 proteins of animal origin were the minimal changes that
ever triggered an inﬂuenza pandemic in humans. The association
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Table  5
Summary of adaptive changes potentially used by zoonotic inﬂuenza viruses to cross animal-to-human transmission barriers, virus–cell interaction barriers, and human-to-
human transmission barriers.
Cross-species transmission barriers Infection  step Factors involved Adaptive changes
Animal-to-human
transmission barriers
Exposure AIV prevalence in reservoir
species
Establishment in domestic animal reservoirs
Contact  with reservoir species Establishment in domestic animal reservoirs
Shared  use of habitats with
reservoir  species
Establishment in domestic animal reservoirs
Site of entry Route of transmission Use of respiratory route of transmission
instead of fecal-oral route of transmission
Potential use of both respiratory and oral
routes of entry for HPAIV H5N1
Virus–cell interaction
barriers
Viral attachment Cell receptors at site of entry
(presence and accessibility)
Switch from 2,3 receptor binding afﬁnity to
2,6 receptor binding afﬁnity
Virus/cell  fusion Host proteases for cleavage of
inﬂuenza virus
Use of respiratory tract tryptases
Acquisition of multi-basic cleavage site
Viral replication Nuclear transport of vRNP Increase in importin-1 binding and switch
from importin-3 to importin-7 dependency
Polymerase activity Increase in interactions between PB2 and NP
proteins
Other unknown mechanisms possibly
associated with protein interactions
Virus  release Nuclear export of vRNP Unknown
Sialidase  activity Match in NA sialidase speciﬁcity to HA
receptor binding afﬁnity
Decrease  in HA receptor binding afﬁnity in
case of low NA sialidase activity
Viral  escape from host
immune  responses
Innate immune responses Disruption of IFN-dependent and
-independent antiviral responses
Regulation of apoptosis pathways
Human-to-human
transmission barriers
Transmission Excretion of high viral titers Use of respiratory route of transmission
Increase in polymerase activity in mammalian
cells
Infection  of upper respiratory
tract
Tissue tropism for upper respiratory tract
associated with 2,6 receptor binding afﬁnity
Increase in polymerase activity at 33 ◦C
Severity  of resulting disease Optimization of tissue tropism
Optimization of polymerase activity
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f a mammalian PB2 gene segment with an avian PB1 gene seg-
ent resulted in high levels of viral replication in mammalian cells
n vitro [174], and may  provide adaptive advantages to reassor-
ants harbouring such combination of genes in a pandemic context.
eassortant viruses carrying only the HA and NA surface proteins of
PAIV H9N2 in a human H3N2 or 2009 pandemic H1N1 backbone
ere transmissible via aerosols in ferrets [175,176]. These studies
emonstrate that novel surface proteins, and notably novel HA pro-
ein, with only minimal changes associated with adaptation to the
ammalian host, may  be sufﬁcient to generate inﬂuenza viruses
ith pandemic potential.
Following  inﬂuenza pandemics, antigenic drift allows the
iruses to recurrently circulate in the human population, causing
nnual seasonal inﬂuenza epidemics. Localized antigenic changes
n the HA protein allow seasonal inﬂuenza viruses to escape
re-existing humoral immunity in a punctuated way [177]. Such
scape from pre-existing immunity results in more extensive epi-
emic waves and more severe disease [178,179]. Recently, the
ize of equine inﬂuenza epidemic waves was estimated based on
he number of amino-acid differences between the HA protein
f strains circulating in the horse population and that of strains
sed to vaccinate horses and against which the horse population
ad measurable levels of pre-existing humoral immunity [180].
t demonstrated that the likelihood of emergence and spread of
quine inﬂuenza viruses was dependent on the immunity land-
cape characterizing the horse population, and for the ﬁrst time
he relationship between immune escape and epidemic poten-
ial was quantiﬁed. The impact of pre-existing cellular immunityOptimization of antiviral escape mechanisms
y Antigenic drift
Antigenic shift
on  inﬂuenza virus epidemiological and evolutionary dynamics is
less clear yet likely non-negligible. This calls for further quantita-
tive studies on pre-existing herd immunity—both antibody- and
cell-mediated—as a major component of human-to-human trans-
mission barriers.
4.3.  Maintenance of inﬂuenza viruses in the human population
Although acquisition of transmissibility is necessary for the
crossing of the human-to-human transmission barriers, it is not suf-
ﬁcient to guarantee sustained spread and maintenance of inﬂuenza
viruses in a susceptible human population. The ability of inﬂuenza
viruses to spread in a host population can be measured by the basic
reproduction number R0, which corresponds to the number of sec-
ondary cases that arise from one infected individual in a well-mixed
susceptible population [181]. R0 is deﬁned mathematically by the
product of the transmission rate and the length of the infectious
period (Eq. (1)).
R0 =
ˇ
 ˛ +  (1)
Here   ˇ is the transmission rate,  ˛ is the virus induced-
mortality/morbidity rate and  is the recovery rate. The length of
the infectious period is deﬁned by 1/(  ˛ + ).
Only viruses with R0 above 1 will successfully spread in a
well-mixed susceptible population and result in an epidemic. As
the epidemic unfolds, the proportion of susceptible individuals (s)
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ecreases as they become infected, recovered and immune, and the
ffective reproductive number (Re) of the virus declines (Eq. (2))
e = sR0. (2)
At  the peak of the epidemic, Re = 1. Thereafter, Re < 1, and local
tochastic extinction of the virus may  occur during the epidemic
rough [182].
As  seen previously, the presence of pre-existing immunity in
he human population can impact inﬂuenza virus probability of
mergence and epidemic dynamics. In addition, variability in sus-
eptibility to infection and in infectiousness, e.g., associated with
ost age or predisposing factors, as well as variability in host
ehaviour that can affect transmission or infectious period can
ave dramatic consequences on the epidemic dynamics and main-
enance of inﬂuenza virus in the human population [183]. For
xample, schoolchildren are considered to play a primary role
n inﬂuenza virus transmission [184,185], and school terms and
olidays in association with heterogenous mixing patterns of indi-
iduals of different age classes can be considered important drivers
f inﬂuenza epidemic dynamics [186,187]. Consequently, hetero-
eneities in the age and network structure of the human population
an signiﬁcantly impact both R0 and the likelihood of continued
aintenance of inﬂuenza virus through epidemics troughs, at spa-
ial scales ranging from that of the household to that of the local,
egional and global community [183]. Such heterogeneities likely
lso impact the probability of emergence of zoonotic inﬂuenza
iruses in the human population and call for further research.
Inﬂuenza virus pathogenicity may  represent another key yet
nder-studied component of human-to-human transmission bar-
iers, by likewise impacting inﬂuenza transmission and infectious
eriod. Inﬂuenza virus pathogenicity determines at least in part
nﬂuenza morbidity and mortality, and the ability and speed of
ecovery. These in turn inﬂuence the infectious period (Eq. (1)).
urthermore, pathogenicity may  inﬂuence transmissibility and
ransmission rate  ˇ by impacting contact rates between infected
nd naïve individuals as well as viral excretion (see below). It is
mportant to note however that only pathogenic effects of inﬂuenza
ccurring during the acute infection may  impact R0.
Severe respiratory disease, such as primary viral pneumonia, can
ccur upon acute inﬂuenza virus infection and results from infec-
ion of epithelial cells in deeper parts of the respiratory tract and
ssociated immune responses [163]. Pneumonia does not induce
oughing and other respiratory signs that may  facilitate aerosol
ransmission of the virus, and strongly impairs infected individuals,
educing their contact with naive individuals. Severe respiratory
esions and associated inﬂammation in the deep lungs may  further
educe excretion of virus particles from these regions due to impair-
ent of the muco-ciliary escalator and mechanical obstruction
f smaller airways. Less severe disease associated with infection
f upper regions of the respiratory tract also is concurrent to
cute infection and associated with the production and release
f cytokines [188]. Although less dramatic than viral pneumonia,
cute tracheo-bronchitis may  as well impair infected individuals
nd reduce contact between infected and naïve individuals. On
he other hand, clinical signs associated with tracheo-bronchitis
nclude coughing, which may  facilitate virus excretion and trans-
ission. As a result, the role of pathogenicity on the ability of
nﬂuenza virus to spread at the population level is difﬁcult to assess,
nd therefore currently poorly understood. While transmissibility
s a prerequisite for zoonotic inﬂuenza viruses to become pandemic,
athogenicity may  have more subtle impact on their ability to suc-
essfully adapt to and sustainably spread in the human population. 30 (2012) 4419– 4434
5.  Conclusions
Three sets of barriers need to be crossed by zoonotic inﬂuenza
viruses to fully adapt to and spread in the human population: (1)
animal-to-human transmission barriers; (2) virus–cell interaction
barriers; and (3) human-to-human transmission barriers. Adap-
tive changes allowing zoonotic inﬂuenza viruses to cross these
barriers have been identiﬁed and represent key knowledge for
improved pandemic preparedness (Table 5). Most of these adaptive
changes link acquired mutations to speciﬁc mechanisms of adapta-
tion that can be screened for, both genetically and phenotypically,
in zoonotic inﬂuenza virus isolates collected as part of inﬂuenza
virus surveillance programs.
The last set of barriers—human-to-human transmission
barriers—nevertheless represents an outstanding challenge for
both inﬂuenza virus, and human understanding. On the one hand,
they appear to be the greatest obstacles against establishment of
zoonotic inﬂuenza viruses in the human population. On  the other
hand, their crossing is at the basis of the most devastating conse-
quences of inﬂuenza virus cross-species transmission. Despite this,
they remain the least understood of inﬂuenza virus cross-species
transmission barriers. First, the determinants of inﬂuenza virus
transmissibility—the initial component of human-to-human trans-
mission barriers—are still elusive. Second, it may  be too tempting
to equate the crossing of human-to-human transmission barriers
with the acquisition of transmissibility, and fail to recognize the
complexity of the last adaptation step to be overcome by zoonotic
inﬂuenza viruses. In 1976, at Fort Dix, in New-Jersey (USA), at
least 230 military personnel were infected by a swine inﬂuenza
virus H1N1 [189]. It caused a short epidemic, simultaneous to
an epidemic caused by seasonal inﬂuenza virus H3N2. Serologic
studies performed at the time demonstrated that heterosubtypic
immunity against the H1N1 virus following infection with the
H3N2 virus seldom occurred, and individuals with an antibody
titer rise to the H1N1 virus were considered to have been infected
with the emerging swine virus. It was  thus a transmissible virus,
yet did not spread beyond the basic combat training population
for unknown reasons. Competition between the emerging and
seasonal viruses, potentially via innate immunity, may  have played
a role in the extinction of the former. Therefore, besides trans-
missibility, additional factors determine the ability of zoonotic
inﬂuenza viruses to spread and be maintained in the human pop-
ulation, causing worldwide pandemic waves eventually leading to
the establishment of human-adapted variants. These additional
factors affect the reproductive ﬁtness of transmissible zoonotic
inﬂuenza viruses and govern their ability to spread in the human
population. In particular, the pathogenicity of an inﬂuenza virus
likely inﬂuences its pandemic potential by impacting transmissi-
bility, contact between infected and naive individuals, and length
of infectious period. In addition, pre-existing immunity modulates
both transmissibility and pathogenicity, and thus affects pandemic
potential. The complexity of the human-to-human transmission
barriers, which act at the level of both individual and population,
requires multidiscipinary research that link virus–cell interac-
tion and immune response within individuals to inﬂuenza virus
dynamics and herd immunity at the population level.
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